Abstract
Aim and Objective: MAO inhibitors have a significant effect on the nervous system since they act in regulation of neurotransmitter concentrations. Neurotransmitter levels are critical for a healthy nervous system. MAO inhibitors can be used in the treatment of neurological disorders such as depression, Parkinson's disease and Alzheimer's disease, as the increase or decrease of some neurotransmitter concentrations is associated with these neurological disorders. This study was conducted to discover new and active MAO inhibitor drug candidates.
Materials and Methods: New pyrazoline derivatives have been designed with the molecular docking approach and interactions of our compounds with the MAO enzyme have been investigated using the Autodock 4.2 program. The designed pyrazoline derivative compounds were synthesized by the reaction of the chalcones and hydrazides in ethanol. hMAO inhibitory activities of the newly synthesized compounds were investigated by fluorimetric method. In vitro cytotoxicity of five most potent inhibitors were tested in HepG2 cells.
Results: (3-(5-bromo-2-hydroxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5i) and (3-(2-hydroxy-4-methoxy phenyl)-5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5l) inhibited hMAO-A more potently than moclobemide (Ki values are 0.004±0.001 and 0.005±0.001, respectively). The same two compounds, 5i and 5l, inhibited hMAO-A more selectively than moclobemide (SI values are 5.55x10-5 and 0.003, respectively). Both of these compounds were found non toxic at 1 µM, 5 µM and 25µM concentrations.
Conclusion: Two of the newly synthesized compounds, (3-(5-bromo-2-hydroxyphenyl)-5-(4- methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl)methanone and (3-(2-hydroxy-4-methoxy phenyl)- 5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone were found to be promising MAO-A inhibitors due to their high inhibitory potency, high selectivity and low toxicity.
Keywords: 2-Pyrazoline, molecular docking, AutoDock 4.2, human MAO, inhibition, synthesis.
Combinatorial Chemistry & High Throughput Screening
Title:Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues
Volume: 20 Issue: 6
Author(s): Begum Evranos-Aksoz*, Gulberk Ucar and Kemal Yelekci
Affiliation:
- Medicines and Medical Devices Agency, Analyses and Control Laboratories, Sıhhıye 06100, Ankara,Turkey
Keywords: 2-Pyrazoline, molecular docking, AutoDock 4.2, human MAO, inhibition, synthesis.
Abstract: Aim and Objective: MAO inhibitors have a significant effect on the nervous system since they act in regulation of neurotransmitter concentrations. Neurotransmitter levels are critical for a healthy nervous system. MAO inhibitors can be used in the treatment of neurological disorders such as depression, Parkinson's disease and Alzheimer's disease, as the increase or decrease of some neurotransmitter concentrations is associated with these neurological disorders. This study was conducted to discover new and active MAO inhibitor drug candidates.
Materials and Methods: New pyrazoline derivatives have been designed with the molecular docking approach and interactions of our compounds with the MAO enzyme have been investigated using the Autodock 4.2 program. The designed pyrazoline derivative compounds were synthesized by the reaction of the chalcones and hydrazides in ethanol. hMAO inhibitory activities of the newly synthesized compounds were investigated by fluorimetric method. In vitro cytotoxicity of five most potent inhibitors were tested in HepG2 cells.
Results: (3-(5-bromo-2-hydroxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5i) and (3-(2-hydroxy-4-methoxy phenyl)-5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5l) inhibited hMAO-A more potently than moclobemide (Ki values are 0.004±0.001 and 0.005±0.001, respectively). The same two compounds, 5i and 5l, inhibited hMAO-A more selectively than moclobemide (SI values are 5.55x10-5 and 0.003, respectively). Both of these compounds were found non toxic at 1 µM, 5 µM and 25µM concentrations.
Conclusion: Two of the newly synthesized compounds, (3-(5-bromo-2-hydroxyphenyl)-5-(4- methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl)methanone and (3-(2-hydroxy-4-methoxy phenyl)- 5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone were found to be promising MAO-A inhibitors due to their high inhibitory potency, high selectivity and low toxicity.
Export Options
About this article
Cite this article as:
Evranos-Aksoz Begum*, Ucar Gulberk and Yelekci Kemal , Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues, Combinatorial Chemistry & High Throughput Screening 2017; 20 (6) . https://dx.doi.org/10.2174/1386207320666170504114208
DOI https://dx.doi.org/10.2174/1386207320666170504114208 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Wnt Signaling through Small molecules in Governing Stem Cell Fate and Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Editorial (Thematic Selection: A Systematic Review of Depression)
Current Neuropharmacology The Effects of Waiting for Treatment: A Meta-analysis of Wait-list Control Groups in Randomized Controlled Trials for Panic Disorder
Current Psychiatry Reviews The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine
Current Cancer Drug Targets Carnosine and Lung Disease
Current Medicinal Chemistry Chronic Psychosocial Stress Exacerbates Impairment of Synaptic Plasticity in β-Amyloid Rat Model of Alzheimers Disease: Prevention by Nicotine
Current Alzheimer Research Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology ERRATUM
Current Neuropharmacology Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Current Pharmaceutical Design Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents
Current Alzheimer Research Cell Therapy Using Induced Pluripotent Stem Cells or Somatic Stem Cells: This is the Question
Current Stem Cell Research & Therapy Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis
Current Reviews in Clinical and Experimental Pharmacology The Effect of Potato Almond Orange Cookies on their Weight, BMI, Hemoglobin, and Lymphocyte Status of Undernourished Older People during COVID-19 Pandemic
Current Nutrition & Food Science Neonatal Immune Activation May Provoke Long-term Depressive Attributes
Current Neurovascular Research Current Neuropharmacology: Supplement 1
Current Neuropharmacology Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Dynamics Simulations of Metalloproteinases Types 2 and 3 Reveal Differences in the Dynamic Behavior of the S1 Binding Pocket
Current Pharmaceutical Design An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice
Current Alzheimer Research Fabrication and Physicochemical and Medicinal Characterization of Nano Traditional Chinese Medicine
Recent Patents on Engineering